Skip to main content

Drug Interactions between armodafinil and Wakix

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

armodafinil pitolisant

Applies to: armodafinil and Wakix (pitolisant)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme.

MANAGEMENT: Pharmacologic response to modafinil or armodafinil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Dose adjustments may be required if an interaction is suspected.

References

  1. Robertson P, Decory HH, Madan A, Parkinson A (2000) "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil." Drug Metab Dispos, 28, p. 664-71
  2. (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc
  3. (2024) "Product Information. Modafinil (modafinil)." Milpharm Ltd
  4. (2023) "Product Information. Modafinil (Apo) (modafinil)." Apotex Pty Ltd
  5. (2024) "Product Information. Apo-Modafinil (modafinil)." Apotex Incorporated
  6. (2024) "Product Information. Modafinil (modafinil)." Heritage Pharmaceuticals Inc
View all 6 references

Drug and food interactions

Minor

armodafinil food

Applies to: armodafinil

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Stimulants

Therapeutic duplication

The recommended maximum number of medicines in the 'stimulants' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'stimulants' category:

  • armodafinil
  • Wakix (pitolisant)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

Duplication

Cerebral stimulants

Therapeutic duplication

The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'cerebral stimulants' category:

  • armodafinil
  • Wakix (pitolisant)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer